IRD vs OCGN: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
IRD (Opus Genetics, Inc.) and OCGN (Ocugen) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
IRD vs OCGN: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | IRD | OCGN | What it tells you |
|---|---|---|---|
| Market cap | $319.47M | $264.61M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -5.37 | -3.08 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.62 | 2.27 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 40% of range | 0% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how IRD and OCGN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IRD and OCGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IRD and OCGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Opus Genetics, Inc. (IRD) do?
Opus Genetics develops treatments for eye disease, and it does so along two tracks that have very little to do with each other. The first is a portfolio of AAV gene therapies for inherited retinal diseases, which is where the ticker comes from: IRD is the industry abbreviation for inherited retinal disease. The lead program, OPGx-LCA5, is in a registrational Phase 3 trial for LCA5-associated blindness and carries FDA Rare Pediatric Disease, Orphan Drug and RMAT designations. Behind it sit OPGx-BEST1 for bestrophin-1 related retinal disease, plus earlier programs targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The second track is phentolamine ophthalmic solution 0.75%, which is already FDA-approved and sold by Viatris as RYZUMVI for reversing dilated pupils after an eye exam, and which is under FDA review for a much larger presbyopia indication with a target action date of October 17, 2026, which was still pending as of October 16. The company was formed when Ocuphire Pharma acquired the private Opus Genetics in late 2024 and took its name, which is why the SEC filer history runs back through Ocuphire and Rexahn.
What does Ocugen (OCGN) do?
Ocugen, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on gene and cell therapies for eye diseases. Its core asset is a modifier gene-therapy platform that uses nuclear hormone receptor genes to address disease across many genetic mutations rather than one at a time. The lead program, OCU400, targets broad retinitis pigmentosa in the Phase 3 liMeliGhT trial; OCU410 targets geographic atrophy secondary to dry age-related macular degeneration; and OCU410ST targets Stargardt disease. The company has framed a goal of pursuing three biologics license applications across these programs, with the first, for OCU400, now planned for the second quarter of 2027 after Phase 3 topline data in the first quarter, and also runs earlier-stage work in other modalities.
IRD vs OCGN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- IRD drivers: The presbyopia decision due October 17, 2026; OPGx-LCA5 is in a registrational trial with a defined path.
- OCGN drivers: Lead program advancing toward a regulatory decision; A platform, not a single shot on goal.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. For OCGN, ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval.
IRD or OCGN: which should you pick?
IRD vs OCGN: the full fundamentals
IRD. No revenue multiple is informative here, because the roughly $9.9 million trailing figure is a development-cost reimbursement that shrinks as programs complete, not a commercial ramp. What the market is pricing instead is the presbyopia royalty stream if the sNDA clears on or around October 17, 2026, the LCA5 Phase 3 asset, and the BEST1 program, against roughly 83 million shares and a balance sheet that does not force a near-term raise. Analyst targets moved up after the September data (Chardan to $16, Wedbush to $13), and the mean target among 17 analysts tracked by Yahoo was about $13.41 in October 2026, far above the $3.87 share price, which says more about the spread of outcomes than about any likely path.
OCGN. Ocugen is pre-profit and has no product revenue, so traditional earnings metrics do not apply; what matters is cash runway versus burn. Cash of ~$100 million at June 30, 2026 followed the 2026 convertible note offering, which management said would extend the runway into 2028, while trailing operating cash outflow ran ~$61 million and the second-quarter loss widened to ~$24.9 million. Analysts expect a loss of about $0.05 per share for the third quarter, with results expected around November 5, 2026. Figures are approximate and can move materially with new raises or spending changes.
Headline figures (approximate, October 2026): IRD shows market cap ~$320M at $3.87 (October 16, 2026), share price range 52-week high ~$7.07, low ~$1.70, revenue (ttm) ~$9.9M, almost entirely Viatris collaboration reimbursement, q2 2026 revenue ~$0.8M, down ~74% from a year earlier; OCGN shows market capitalization ~$273 million at ~$0.80 per share (Oct 16, 2026), shares outstanding ~339 million, revenue (ttm, collaboration/other) ~$4.6 million, net loss (ttm) ~$81.8 million (~$0.26 per share).
The bottom line: IRD vs OCGN
IRD and OCGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IRD and OCGN exposure against your real portfolio. It is not an investment adviser.
Wondering how IRD or OCGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Opus Genetics, Inc. with AI
Connect the broker you already use and ask Walnut's AI how IRD fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between IRD and OCGN?
+
Opus Genetics develops treatments for eye disease, and it does so along two tracks that have very little to do with each other. Ocugen, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is IRD or OCGN the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, IRD or OCGN?
+
On forward P/E (as of October 2026), IRD trades at -5.37x and OCGN at -3.08x, so IRD is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both IRD and OCGN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of IRD vs OCGN?
+
IRD: The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. The BEST1 data that moved the stock more than 50 percent in September 2026 (a gain it largely gave back, falling about 25% in the following month) came from five patients in an open-label, uncontrolled cohort, and single-arm improvements in small numbers of retinal patients have historically failed to replicate in randomized trials. Revenue is falling rather than growing, because it is Viatris reimbursing development costs rather than product sales, and the phentolamine franchise is commercially controlled by Viatris, so Opus captures only royalties and milestones from whatever the drug becomes. The October 17, 2026 PDUFA date is a genuine binary: a complete response letter would remove the nearest source of non-dilutive cash. Inherited retinal disease markets are also very small in patient count and expensive to serve, AAV gene therapy carries a long industry history of manufacturing and immune-response setbacks, and the Oberland facility is debt-like capital whose obligations sit ahead of shareholders. OCGN: Ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval. The company funds itself from a limited cash balance and recurring capital raises, and it has historically issued equity and convertible debt that dilute existing shareholders. It competes with larger, better-funded gene-therapy and ophthalmology developers. A single negative readout or regulatory setback could sharply reduce the stock's value. Two newer risks apply as of October 2026. The shares closed at ~$0.80 on October 16, below Nasdaq's $1.00 minimum bid requirement, and a sustained period under that level can trigger a deficiency notice and, if not cured, a reverse split or delisting. The U.S. BLA timeline has also moved out, from a rolling filing guided for the third quarter of 2026 to a planned submission in the second quarter of 2027, which lengthens the period the company must fund before any U.S. approval decision.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IRD or OCGN; figures are approximate and dated (as of October 2026). Verify current data before investing.